Your browser doesn't support javascript.
loading
The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG).
Buske, C; Hoster, E; Dreyling, M; Eimermacher, H; Wandt, H; Metzner, B; Fuchs, R; Bittenbring, J; Woermann, B; Hohloch, K; Hess, G; Ludwig, W-D; Schimke, J; Schmitz, S; Kneba, M; Reiser, M; Graeven, U; Klapper, W; Unterhalt, M; Hiddemann, W.
Afiliação
  • Buske C; Department of Internal Medicine III, University of Munich, Munich, Germany. christian.buske@med.uni-muenchen.de
Leukemia ; 23(1): 153-61, 2009 Jan.
Article em En | MEDLINE | ID: mdl-18818699
ABSTRACT
Lymphoplasmacytic lymphoma (LPL) is an indolent lymphoma with moderate sensitivity to conventional chemotherapy. This study investigated whether the addition of rituximab to standard chemotherapy improves treatment outcome in LPL and the subgroup of LPL patients fulfilling the criteria of Waldenstroem's macroglobulinemia (WM). A total of 69 patients with previously untreated LPL were enrolled into the trial; 64 patients were evaluable for treatment outcome. In all, 48 of the 64 LPL patients fulfilled the criteria of WM. Patients were randomly assigned to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, n=34) or CHOP (n=30). R-CHOP resulted in significantly higher overall response (OR) rate (94 vs 67%, P=0.0085) in the LPL patients and in the WM subgroup (91 vs 60%, P=0.0188). With a median observation time of 42 months, R-CHOP induced a significantly longer time to treatment failure (TTF) with a median of 63 months for R-CHOP vs 22 months in the CHOP arm in the LPL patients (P=0.0033) and in the WM subgroup (P=0.0241). There was no major difference of treatment-associated toxicity between both treatment groups. These data indicate that the addition of rituximab to front-line chemotherapy improves treatment outcome in patients with LPL or WM.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Macroglobulinemia de Waldenstrom / Anticorpos Monoclonais Idioma: En Ano de publicação: 2009 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Macroglobulinemia de Waldenstrom / Anticorpos Monoclonais Idioma: En Ano de publicação: 2009 Tipo de documento: Article